WO2015181365A1 - Cyclodextrin-grafted hyaluronic acid crosslinked with dextran and uses thereof - Google Patents

Cyclodextrin-grafted hyaluronic acid crosslinked with dextran and uses thereof Download PDF

Info

Publication number
WO2015181365A1
WO2015181365A1 PCT/EP2015/061999 EP2015061999W WO2015181365A1 WO 2015181365 A1 WO2015181365 A1 WO 2015181365A1 EP 2015061999 W EP2015061999 W EP 2015061999W WO 2015181365 A1 WO2015181365 A1 WO 2015181365A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
hyaluronic acid
molecule
process according
hydrogel product
Prior art date
Application number
PCT/EP2015/061999
Other languages
French (fr)
Inventor
Jean-Guy Boiteau
Original Assignee
Galderma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma S.A. filed Critical Galderma S.A.
Priority to EP15726137.1A priority Critical patent/EP3148600B1/en
Priority to US15/314,823 priority patent/US20170196991A1/en
Publication of WO2015181365A1 publication Critical patent/WO2015181365A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/02—Dextran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/16—Cyclodextrin; Derivatives thereof

Definitions

  • hyaluronic acid is a naturally occurring polysaccharide belonging to the group of glycosaminoglycans (GAGs).
  • GAGs glycosaminoglycans
  • Hyaluronic acid and the other GAGs are negatively charged heteropolysaccharide chains which have a capacity to absorb large amounts of water.
  • Hyaluronic acid and products derived from hyaluronic acid are widely used in the biomedical and cosmetic fields, for instance during viscosurgery and as a dermal filler.
  • the guest When a hydrophobic molecule (the guest) is contained, fully or partially, within the interior of the cyclodextrin (the host), this is referred to as an inclusion complex or guest/host complex.
  • the formation of the guest/host complex can greatly modify the physical and chemical properties of the guest molecule, mostly in terms of water solubility. This is a reason why
  • the hydrogel product is further comprising a guest molecule capable of forming a guest-host complex with the cyclodextrin molecule acting as a host.
  • the guest molecule may be selected from drugs and/or biologically active substances used in the treatment of disorders in the field of dermatology, aesthetics, ophthalmology, gynaecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology.
  • the grafting of step (b) provides amide bonds between the one or more cyclodextrin molecules and the hyaluronic acid.
  • the cyclodextrin molecule contains a linking group having an amino group, and wherein the linking group of the cyclodextrin molecule forms said amide bond with a carboxyl group of the hyaluronic acid.
  • Certain linking groups contain a Ci-6 alkyl or Ci-6 alkyl linker.
  • the hyaluronic acid can be obtained from various sources of animal and non-animal origin.
  • Sources of non-animal origin include yeast and preferably bacteria.
  • the molecular weight of a single hyaluronic acid molecule is typically in the range of 0.1 -10 MDa, but other molecular weights are possible.
  • concentration of the cross-linked polymer mixture is in the range of 2 to 50 mg/ml. In specific embodiments the concentration of the cross-polymer mixture is in the range of 5 to 30 mg/ml or in the range of 10 to 30 mg/ml.
  • crosslinking agent Reaction conditions for crosslinking and suitable analytical techniques for determining the degree of modification are all well known to the person skilled in the art, who easily can adjust these and other relevant factors and thereby provide suitable conditions to obtain a degree of modification in the range of 0.1 -2% and verify the resulting product
  • a BDDE (1 ,4- butandiol diglycidylether) crosslinked dextran/hyaluronic acid gel may for example be prepared analogously to the method described in Examples 1 , 2 or 7 of published international patent application WO 9704012.
  • the hydrogel product is present in the form of particles, strings, discs, etc.
  • the cross-linked hydrogel is in the form of gel particles.
  • the gel particles preferably have an average size in the range of 0.01 -5 mm, preferably 0.1 -0.8 mm, such as 0.2-0.5 mm or 0.5-0.8 mm.
  • the hydrogel product may be present in an aqueous solution, but it may also be present in dried or precipitated form, e.g. in a suitable precipitant liquid.
  • the hydrogel product is preferably injectable.
  • the guest molecule is preferably selected from drugs and/or biologically active substances used in the treatment of disorders in the field of dermatology, aesthetics, ophthalmology, gynaecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology, such as anti-infective agents, antimicrobials, anti-inflammatory agents, cytostatic, cytotoxic, antiviral, anaesthetic, hemostatic, vasoconstrictor agents or growth factors.
  • drugs and/or biologically active substances used in the treatment of disorders in the field of dermatology, aesthetics, ophthalmology, gynaecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology, such as anti-infective agents, antimicrobials, anti-inflammatory agents, cytostatic, cytotoxic, antiviral, anaesthetic, hemostatic, vasoconstrictor agents or growth factors.
  • the guest molecule is a vitamin A molecule, such as retinol or retinoic acid, or an ester or an ether thereof.
  • the hydrogel product according to the invention is thus useful as a medicament, e.g. in the treatment of a condition susceptible to treatment by said guest molecule.
  • the cross-linking of step (c) provides ether bonds between the dextran and the cyclodextrin-grafted hyaluronic acid.
  • the amide bonds are formed between the amino group of amino-cyclodextrins having 6-8 glucopyranoside units and the carboxylic acid group of hyaluronic acid, followed by cross-linking with dextran and size reduction of the resulting gel to provide ether cross-linked dextran/hyaluronic acid gel particles with grafted cyclodextrins.
  • This amide bond is realized by a peptide coupling agent, such as DMTMM.
  • Table 1 Compiled from A. Maqnusdottir, M. Masson and T. Loftsson, J. Incl.

Abstract

A hydrogel product comprising (a) one or more cyclodextrin molecules grafted to hyaluronic acid and (b) dextran, wherein the cyclodextrin-grafted hyaluronic acid is cross-linked to the dextran. The one or more cyclodextrin molecules are grafted, e.g. by amide bonds, to the hyaluronic acid prior to the cross- linking with dextran.

Description

CYCLODEXTRIN-GRAFTED HYALURONIC ACID CROSSLINKED WITH DEXTRAN AND USES THEREOF
Technical field of the invention
The present invention relates to the field of hydrogels containing cross- linked polysaccharides and the use of such hydrogels in medical and/or cosmetic applications. More specifically, the present invention deals with cross-linked hydrogels containing hyaluronic acid and dextran, functionalized with cyclodextrin.
Background of the invention
One of the most widely used biocompatible polymers for medical use is hyaluronic acid (HA). It is a naturally occurring polysaccharide belonging to the group of glycosaminoglycans (GAGs). Hyaluronic acid and the other GAGs are negatively charged heteropolysaccharide chains which have a capacity to absorb large amounts of water. Hyaluronic acid and products derived from hyaluronic acid are widely used in the biomedical and cosmetic fields, for instance during viscosurgery and as a dermal filler.
Water-absorbing gels, or hydrogels, are widely used in the biomedical field. They are generally prepared by chemical crosslinking of polymers to infinite networks. While native hyaluronic acid and certain crosslinked hyaluronic acid products absorb water until they are completely dissolved, crosslinked hyaluronic acid gels typically absorb a certain amount of water until they are saturated, i.e. they have a finite liquid retention capacity, or swelling degree.
Since hyaluronic acid is present with identical chemical structure except for its molecular mass in most living organisms, it gives a minimum of reactions and allows for advanced medical uses. Crosslinking and/or other modifications of the hyaluronic acid molecule is necessary to improve its duration in vivo. Furthermore, such modifications affect the liquid retention capacity of the hyaluronic acid molecule. As a consequence thereof, hyaluronic acid has been the subject of many modification attempts. Another widely used biocompatible polymer is dextran. Dextran is a complex, branched glucan composed of chains of varying lengths (from 3 to 2000 kD). The straight chain consists of a-1 ,6 glycosidic linkages between glucose molecules, while branches begin from a-1 ,3 linkages.
Cyclodextrins (sometimes called cycloamyloses), also referred to herein as CDs, are a family of compounds made up of sugar molecules bound together in a ring (cyclic oligosaccharides). Cyclodextrins are produced from starch by means of enzymatic conversion. Typically, cyclodextrins are constituted by 6-8 glucopyranoside units, and have a structural conformation resembling toroids with the primary hydroxyl groups of the glucopyranoside units arranged along the smaller opening of the toroid and the secondary hydroxyl groups of the glucopyranoside units arranged along the larger opening of the toroid. Because of this arrangement, the interior of the toroids is considerably less hydrophilic than the aqueous environment and thus able to host other hydrophobic molecules. In contrast, the exterior is sufficiently hydrophilic to impart cyclodextrins (or their complexes) water solubility.
When a hydrophobic molecule (the guest) is contained, fully or partially, within the interior of the cyclodextrin (the host), this is referred to as an inclusion complex or guest/host complex. The formation of the guest/host complex can greatly modify the physical and chemical properties of the guest molecule, mostly in terms of water solubility. This is a reason why
cyclodextrins have attracted much interest in pharmaceutical applications: because inclusion compounds of cyclodextrins with hydrophobic molecules are able to penetrate body tissues, these can be used to release biologically active compounds under specific conditions. In most cases the mechanism of controlled degradation of such complexes is based on change of pH, leading to the cleavage of hydrogen or ionic bonds between the host and the guest molecules. Other mechanisms for the disruption of the complexes include heating or action of enzymes able to cleave a-1 ,4 linkages between glucose monomers. Summary of the invention
It is an object of the present invention to provide improved formulations for administration of pharmaceutical and/or cosmetic substances.
In particular, it is an object of the present invention to provide a cross- linked hydrogel product having a significant amount of grafted cyclodextrins.
It is also an object of the present invention to provide a process for preparing improved formulations for administration of pharmaceutical and/or cosmetic substances.
In particular, it is an object of the present invention to provide a process for providing a cross-linked hydrogel product having a significant amount of grafted cyclodextrins.
For these and other objects that will be evident from this disclosure, the present invention provides according to a first aspect a hydrogel product comprising (a) one or more cyclodextrin molecules grafted to hyaluronic acid and (ii) dextran, wherein the cyclodextrin-g rafted hyaluronic acid is cross- linked to the dextran.
It is advantageous to graft the cyclodextrin molecules on the hyaluronic acid prior to the cross-linking between the polymers, since this makes the final gel product more homogenous with respect to cyclodextrin distribution. In certain applications, for instance slow release administration of drug molecules, it may be particularly useful to have an even distribution of the cyclodextrins throughout the gel product.
In certain preferred embodiments, the dextran is cross-linked to the cyclodextrin-grafted hyaluronic acid by ether bonds.
In some preferred embodiments, the one or more cyclodextrin molecules are grafted onto the hyaluronic acid by amide bonds.
According to a preferred embodiment, the cross-linked hydrogel product is in the form of gel particles having an average size in the range of 0.01 -5 mm, preferably 0.1 -0.8 mm.
According to one preferred embodiment, the dextran and the hyaluronic acid chains are cross-linked to each other via a linking group which is derived from a bi- or polyfunctional cross-linking agent, such as a diglycidyl ether, e.g. 1 ,4-butanediol diglycidyl ether (BDDE). According to a preferred embodiment, the cyclodextrin molecule contains a linking group having an amino group, and wherein the linking group of the cyclodextrin molecule forms said amide bond with a carboxyl group of the hyaluronic acid. Certain linking groups contain a Ci-6 alkyl or Ci-6 alkyl linker.
The linking group can also be an amino group. A preferred group of cyclodextrin molecules are aminocyclodextrins, such as α-, β- or γ- cyclodextrins, of which 2-aminocyclodextrin, 3-aminocyclodextrin and 6- aminocyclodextrin are preferred.
According to one preferred embodiment, the hydrogel product is further comprising a guest molecule capable of forming a guest-host complex with the cyclodextrin molecule acting as a host. The guest molecule may be selected from drugs and/or biologically active substances used in the treatment of disorders in the field of dermatology, aesthetics, ophthalmology, gynaecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology.
According to another aspect, the present invention provides a process of preparing a hydrogel product comprising, comprising the steps of:
(a) providing (i) hyaluronic acid, (ii) dextran, and (iii) one or more cyclodextrin molecules;
(b) grafting the one or more cyclodextrin molecules onto the hyaluronic acid to form a cyclodextrin-grafted hyaluronic acid; and
(c) cross-linking the cyclodextrin-grafted hyaluronic acid to the dextran using a bi- or polyfunctional cross-linking agent.
It has been realized that grafting of the cyclodextrin molecules onto the hyaluronic acid prior to the cross-linking with dextran is associated with a more homogenous cyclodextrin distribution in the final gel product.
In certain preferred embodiments, the cross-linking of step (c) provides ether bonds between the dextran and the cyclodextrin-grafted hyaluronic acid.
In some preferred embodiments, the grafting of step (b) provides amide bonds between the one or more cyclodextrin molecules and the hyaluronic acid. According to a preferred embodiment, the cyclodextrin molecule contains a linking group having an amino group, and wherein the linking group of the cyclodextrin molecule forms said amide bond with a carboxyl group of the hyaluronic acid. Certain linking groups contain a Ci-6 alkyl or Ci-6 alkyl linker.
The linking group can also be an amino group. A preferred group of cyclodextrin molecules are aminocyclodextrins, such as α-, β- or γ- cyclodextrins, of which 2-aminocyclodextrin, 3-aminocyclodextrin and 6- aminocyclodextrin are preferred.
In a preferred embodiment, the grafting of step (b) involves:
(i) activating the carboxyl groups on the hyaluronic acid with a peptide coupling reagent to form an activated hyaluronic acid; and
(ii) coupling the linking group of the one or more cyclodextrin molecules to the carboxyl groups of the activated hyaluronic acid by amide bonds.
In one preferred embodiment, the peptide coupling reagent is selected from the group consisting of triazine-based coupling reagents, carbodiimide coupling reagents, imidazolium-derived coupling reagents, Oxyma and COMU. The peptide coupling reagent is preferably a triazine-based coupling reagent, such as 4-(4,6-dimethoxy-1 ,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM).
According to a related aspect, the present invention provides a process of preparing a formulation of a guest molecule capable of forming a guest- host complex with a cyclodextrin host molecule, comprising the steps:
(a) providing (i) hyaluronic acid, (ii) dextran and (ii) one or more cyclodextrin host molecules capable of forming a guest-host complex with the guest molecule;
(b) grafting the one or more cyclodextrin host molecules onto the hyaluronic acid to form a cyclodextrin-grafted hyaluronic acid; and
c) cross-linking the cyclodextrin-grafted hyaluronic acid to the dextran using a bi- or polyfunctional cross-linking agent to form a cross-linked hydrogel.
d) bringing a solution of the guest molecule into contact with the cyclodextrin host molecules grafted onto the hyaluronic acid under conditions allowing for the formation of a guest-host complex between the cyclodextrin host molecules and the guest molecule, and optionally
e) recovering the guest-host complex bound to the cross-linked hydrogel.
In certain preferred embodiments, the cross-linking of step (c) provides ether bonds between the dextran and the cyclodextrin-grafted hyaluronic acid.
In some preferred embodiments, the grafting of step (b) provides amide bonds between the one or more cyclodextrin molecules and the hyaluronic acid.
The guest molecule may be selected from drugs and/or biologically active substances used in the treatment of disorders in the field of
dermatology, aesthetics, ophthalmology, gynaecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology.
Other aspects and preferred embodiments of the present invention will be evident from the following detailed disclosure of the invention and the appended claims.
Brief description of the drawing
Fig. 1 shows reaction of HA with amino-cyclodextrin and DMTMM (step 1 , grafting), followed by reaction with dextran and BDDE (step 2, cross- linking).
Detailed description of the invention
The present invention generally provides a hydrogel of a cross-linked polymer mixture with grafted cyclodextrin molecules grafted. The hydrogel product is comprising one or more cyclodextrin molecules which are grafted onto the hyaluronic acid, preferably by amide bonds. The hydrogel product is further comprising dextran which is cross-linked to the cyclodextrin-grafted hyaluronic acid, preferably by ether bonds.
In a preferred embodiment, the invention deals with production of hyaluronic acid (HA) grafted with cyclodextrins, e.g. amino-cyclodextrins using peptidic coupling, wherafter this functionalized polysaccharide is linked to dextran by the use of a diepoxide linker like butanediol diglycidyl ether
(BDDE). An amino-cyclodexthn can be linked to HA by an amide bond via a spacer or without a spacer. The optional spacer can be represented by X-N and can be any of the linker known by a person skilled in the art. X can also be equal to zero, that means in this case that the amino-cyclodextrin is directly linked to HA by the amide bond. This amide bond can be realized by reaction of an amino group of amino-cyclodextrin with the carboxylic group of glucuronic acids using a peptidic coupling reagent like DMTMM as depicted in Fig. 1 , step 1 .
The cyclodextrin grafted HA can be linked to dextran by an ether bond between one hydroxyl group of HA with the hydroxyl group of dextran. This ether bond between the two components can be realized by means of a diepoxide linker like butanediol diglycidyl ether (BDDE) as depicted in Fig. 1 , step 2, which also provides a spacer between the HA and the dextran.
Unless otherwise provided, the term "dextran" encompasses all variants and combinations of variants of dextran, of various chain lengths and charge states, as well as with various chemical modifications. Dextran is a complex, branched glucan composed of chains of varying lengths (from 3 to 2000 kD). The straight chain consists of a-1 ,6 glycosidic linkages between glucose molecules, while branches begin from a-1 ,3 linkages. Dextran is a bacterial polysaccharide and may be synthesized from sucrose by certain lactic-acid bacteria, for example, Leuconostoc mesenteroides and
Streptococcus mutans.
Unless otherwise provided, the term "hyaluronic acid" encompasses all variants and combinations of variants of hyaluronic acid, hyaluronate or hyaluronan, of various chain lengths and charge states, as well as with various chemical modifications. That is, the term also encompasses the various hyaluronate salts of hyaluronic acid with various counter ions, such as sodium hyaluronate. Various modifications of the hyaluronic acid are also encompassed by the term, such as oxidation, e.g. oxidation of -CH2OH groups to -CHO and/or -COOH; periodate oxidation of vicinal hydroxyl groups, optionally followed by reduction, e.g. reduction of -CHO to -CH2OH or coupling with amines to form imines followed by reduction to secondary amines; sulphation; deamidation, optionally followed by deamination or amide formation with new acids; esterification; and deacetylation. Other examples of modifications are isourea, hydrazide, bromocyan, monoepoxide and monosulfone couplings.
The hyaluronic acid can be obtained from various sources of animal and non-animal origin. Sources of non-animal origin include yeast and preferably bacteria. The molecular weight of a single hyaluronic acid molecule is typically in the range of 0.1 -10 MDa, but other molecular weights are possible.
A critical feature of the present invention is that the cyclodextrin molecules are grafted onto the hyaluronic acid chains prior to their cross- linking to the dextran chains, preferably by amide bonds to the carboxyl groups of the hyaluronic acid. Grafting of the cyclodextrin molecules onto the hyaluronic acid prior to the cross-linking with dextran is associated with a more homogenous cyclodextrin distribution in the final gel product. The resulting cross-linked hydrogel product is thus suitable for slow-release applications. It is preferred that the cyclodextrin molecules and the
disaccharides of the cross-linked hyaluronic acid have a molar ratio of 0.1 - 50%, preferably 1 -20%, and more preferably 8-12%.
The cyclodextrin molecules are useful as carriers (hosts) for a pharmaceutical agent (guest). When a pharmaceutical agent (the guest) is contained, fully or partially, within the interior of the cyclodextrin (the host), this is referred to as an inclusion complex or guest/host complex. The cyclodextrin may then release the pharmaceutical agent under specific conditions, e.g. due to change in pH leading to the cleavage of hydrogen or ionic bonds between the host and the guest molecules.
The cyclodextrin molecules are attached to the the hyaluronic acid component of the cross-linked polymer mixture in order to reduce migration of the cyclodextrin (or guest/host complex) from the site of administration, e.g. injection. In this way, the site of release of the pharmaceutical agent from the cyclodextrin can be controlled.
Also, in order to increase temporal control of the release of the pharmaceutical agent, it has been found that the influence of cleavage of the bonds between the cyclodextrin (or guest/host complex) and the cross-linked polymer mixture should be minimized. In other words, it is desired that the release of the pharmaceutical agent is, as far as possible dependent on the physical release from the cyclodextrin rather than on chemical degradation.
In preferred hydrogel products, the cyclodextrin molecules are attached to the hyaluronic acid by amide bonds. The use of amide bonds in the cyclodextrin-hyaluronic acid linkage (graft) has been found to be
advantageous compared to e.g. ester bonds, since the amide bond is more stable to degradation in the subsequent cross-linking step as well as in vivo. The use of a less stable bond between the hyaluronic acid and cyclodextrin molecules could lead to premature loss of cyclodextrin (or guest/host complex) from the site of injection.
The cyclodextrin of the hydrogel product may in practice be any cyclodextrin capable of acting as the host molecule in a guest/host complex together with a pharmaceutical agent. Cyclodextnns may generally be constituted by 5-32 glucopyranoside units. However, cyclodextrins constituted by 6-8 glucopyranoside units are generally preferred for the formation of guest/host complexes with pharmaceutical agents. Cyclodextrins constituted by 6, 7 and 8 glucopyranoside units are often referred to as α-, β- and γ- cyclodextrins respectively. According to an embodiment, the cyclodextrin molecules are constituted by 6 glucopyranoside units (a-cyclodextrin).
According to an embodiment, the cyclodextrin molecules are constituted by 7 glucopyranoside units (β-cyclodextrin). According to an embodiment, the cyclodextrin molecules are constituted by 8 glucopyranoside units (γ- cyclodextrin).
Cyclodextrins are often chemically modified in order to improve their solubility in water and/or to optimize their performance in a specific
application. The term cyclodextrin, a-cyclodextrin, β-cyclodextrin and v- cyclodextrin, as used herein is also intended to encompass the functionally equivalent variants or derivatives thereof. Examples of such chemically modified cyclodextrins include, but are not limited to, hydroxypropyl and methyl cyclodextrins.
Examples of modified a-cyclodextrins for use with the hydrogel composition include, but are not limited to, hydroxypropyl-a-cyclodextrin. Examples of modified β-cyclodextrins for use with the hydrogel composition include, but are not limited to, hydroxypropyl- -cyclodextrin; 2,6- di-O-methyl- -cyclodextrin; 6-O-maltosyl- -cyclodextrin; 2-hydroxypropyl- - cyclodextrin; methyl- -cyclodextrin; sulfobutyl- -cyclodextrin;
monochlorotriazinyl- -cyclodextrin; heptakis (2- -amino-O-oligo (ethylene oxide)-6-hexylthio)- -cyclodextrin; ethylenediamino or diethylenetriamino bridged bis( cyclodextrin)s; randomly methylated β-cyclodextrin;
sulfobutyl ether- -cyclodextrin; and monochlorotriazinyl- -cyclodextrin.
Examples of modified γ-cyclodextrins for use with the hydrogel composition include, but are not limited to, γ-cyclodextrin C6, and 2,3-di-O- hexanoyl-γ cyclodextrin. Further additional modified cyclodextrins are also shown in Tables 1 -3 herein.
According to the invention, it is preferred that the cyclodextrin molecule contains a linking group having an amino group. The linking group is covalently attached to the cyclodextrin backbone and may include a spacer molecule, such as Ci-6 alkyl or Ci-4 alkyl. The linking group of the cyclodextrin molecule preferably forms an amide bond with a carboxyl group of the hyaluronic acid. It is preferred that the linking group has or is an amino group. In a preferred embodiment, the cyclodextrin molecule is an aminocyclodextrin molecule, and the amino group of the aminocyclodextrin molecule forms the amide bond with a carboxyl group of the hyaluronic acid.
A preferred group of cyclodextrin molecules are aminocyclodextrin molecules constituted by 6-8 glucopyranoside units, such as 6
glucopyranoside units (a-cyclodextrin), 7 glucopyranoside units
(β-cyclodextrin) or 8 glucopyranoside units (γ-cyclodextrin). It is then furthermore preferred that the cyclodextrin molecule is selected from the group consisting of 2-aminocyclodextrin, 3-aminocyclodextrin and 6- aminocyclodextrin, preferably from the group consisting of 3- aminocyclodextrin and 6-aminocyclodextrin. A preferred cyclodextrin molecule is 6-aminocyclodextrin.
The hydrogel product according to the invention is comprising a cross- linked polymer mixture, consisting of dextran cross-linked to cyclodextrin- grafted (functionalized) hyaluronic acid. It follows that there are covalent cross-links between the dextran chains and the hyaluronic acid chains, the latter of which have previously been grafted with the cyclodextrin(s). It is understood that the in the general case, the cross-linking process between dextran and hyaluronic acid is complex and will in addition to the these cross- links also provide covalent cross-links between the hyaluronic acid chains as well as between the dextran chains. Together, this creates a continuous network of dextran and hyaluronic acid molecules which is held together by the covalent crosslinks, physical entangling of the polymer chains and various interactions, such as electrostatic interactions, hydrogen bonding and van der Waa Is forces.
In certain embodiments, the concentration of the cross-linked polymer mixture is in the range of 1 to 100 mg/ml. In some embodiments the
concentration of the cross-linked polymer mixture is in the range of 2 to 50 mg/ml. In specific embodiments the concentration of the cross-polymer mixture is in the range of 5 to 30 mg/ml or in the range of 10 to 30 mg/ml.
The weight ratio between the dextran and the hyaluronic acid in the cross-linked polymer mixture may vary to large extent, typically from 100:1 to 1 :100, such as from 10:1 to 1 :10, e.g. from 5:1 to 1 :5.
The crosslinked hydrogel product is preferably biocompatible. This implies that no, or only very mild, immune response occurs in the treated individual. That is, no or only very mild undesirable local or systemic effects occur in the treated individual.
The crosslinked product according to the invention is a gel, or a hydrogel. That is, it can be regarded as a water-insoluble, but substantially dilute crosslinked system of dextran and hyaluronic acid molecules when subjected to a liquid, typically an aqueous liquid.
The gel contains mostly liquid by weight and can e.g. contain 90-99.9% water, but it behaves like a solid due to a three-dimensional crosslinked polymer network within the liquid. Due to its significant liquid content, the gel is structurally flexible and similar to natural tissue, which makes it very useful as a scaffold in tissue engineering and for tissue augmentation.
Crosslinking of the dextran to the cyclodextrin-grafted (functionalized) hyaluronic acid may be achieved by modification with a crosslinking agent. The polymer concentrations and the extent of crosslinking affects the mechanical properties, e.g. the elastic modulus G', and stability properties of the gel. Crosslinked polymer gels are often characterized in terms of "degree of modification". The degree of modification of hyaluronic acid-containg gels generally range between 0.1 and 15 mole%. The degree of HA modification (mole%) describes the amount of crosslinking agent(s) that is bound to HA, i.e. molar amount of bound crosslinking agent(s) relative to the total molar amount of repeating HA disaccharide units. The degree of modification reflects to what degree the HA has been chemically modified by the
crosslinking agent. Reaction conditions for crosslinking and suitable analytical techniques for determining the degree of modification are all well known to the person skilled in the art, who easily can adjust these and other relevant factors and thereby provide suitable conditions to obtain a degree of modification in the range of 0.1 -2% and verify the resulting product
characteristics with respect to the degree of modification. A BDDE (1 ,4- butandiol diglycidylether) crosslinked dextran/hyaluronic acid gel may for example be prepared analogously to the method described in Examples 1 , 2 or 7 of published international patent application WO 9704012.
In a preferred embodiment, the hydrogel product is present in the form of a gel crosslinked by a crosslinking agent, wherein the concentration of said polymers is in the range of 10 to 30 mg/ml, and the degree of HA modification with said crosslinking agent is in the range of 0.1 to 2 mole%.
The hydrogels may also comprise a portion of dextran and/or hyaluronic acid which is not crosslinked, i.e not bound to the three- dimensional crosslinked hyaluronic acid network. However, it is preferred that at least 50 % by weight, preferably at least 60 % by weight, more preferably at least 70 % by weight, and most preferably at least 80 % by weight, of the dextran and hyaluronic acid in a gel composition form part of the crosslinked polymer network.
The hydrogel product is present in the form of particles, strings, discs, etc. In a preferred embodiment, the cross-linked hydrogel is in the form of gel particles. The gel particles preferably have an average size in the range of 0.01 -5 mm, preferably 0.1 -0.8 mm, such as 0.2-0.5 mm or 0.5-0.8 mm. The hydrogel product may be present in an aqueous solution, but it may also be present in dried or precipitated form, e.g. in a suitable precipitant liquid. The hydrogel product is preferably injectable.
The dextran and the hyaluronic acid chains are preferably cross-linked to each other via a linking group which is derived from a bi- or polyfunctional cross-linking agent. The bi- or polyfunctional crosslinking agent of the hydrogel product connects the dextran to the hyaluronic acid. The bi- or polyfunctional crosslinking agent further acts as a spacer between the dextran and the hyaluronic acid.
The bi- or polyfunctional crosslinking agent comprises two or more functional groups capable of reacting with functional groups of the dextran and the hyaluronic acid, respectively, resulting in the formation of covalent bonds. The bi- or polyfunctional crosslinking agent may for example selected from the group consisting of divinyl sulfone, multiepoxides and diepoxides.
A preferred type of bi- or polyfunctional cross-linking agent is a bis- or polyepoxide, such as a diglycidyl ether. According to an embodiment, the bi- or polyfunctional crosslinking agent comprises two or more glycidyl ether functional groups. The glycidyl ether functional groups react with primary hydroxyl groups of the dextrans and the hyaluronic acid, respectively, resulting in the formation of ether bonds. It follows that when a diglycidyl ether cross-linking agent reacts with the primary hydroxyl groups of these polymers, two ether bonds are formed with an intermediate spacer remaining from the cross-linking agent,
Preferred bi- or polyfunctional cross-linking agent for cross-linking the dextran and the hyaluronic acid chains include 1 ,4-butanediol diglycidyl ether (BDDE), 1 ,2-bis(2,3-epoxypropoxy)ethylene (EGDGE) and ethylene glycol diglycidyl ether (EGDE), 1 ,2-ethanediol diglycidyl ether (EDDE) and
diepoxyoctane. A particularly preferred bi- or polyfunctional cross-linking agent is BDDE.
The hydrogel product disclosed herein may advantageously be used for the transport or administration and slow or controlled release of various pharmaceutical or cosmetic substances. The hydrogel product may also comprise a guest molecule capable of forming a guest-host complex with the cyclodextrin molecule acting as a host. The guest molecule is generally hydrophobic or lipophilic or has a
portion/moiety which is hydrophobic or lipophilic. The size and properties of the guest molecule determines which cyclodextrin is suitable as host. Much effort has been invested in the scientific field to determine suitable
cyclodextrin host molecules for various pharmaceutical guest molecules. Some of the guest-host complexes identified are presented in Tables 1 -3 herein.
The guest molecule is preferably selected from drugs and/or biologically active substances used in the treatment of disorders in the field of dermatology, aesthetics, ophthalmology, gynaecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology, such as anti-infective agents, antimicrobials, anti-inflammatory agents, cytostatic, cytotoxic, antiviral, anaesthetic, hemostatic, vasoconstrictor agents or growth factors.
According to a preferred embodiment, the guest molecule is a vitamin A molecule, such as retinol or retinoic acid, or an ester or an ether thereof.
The hydrogel product according to the invention is thus useful as a medicament, e.g. in the treatment of a condition susceptible to treatment by said guest molecule.
The hydrogel product is also useful for the manufacture of a
medicament for treatment of a condition susceptible to treatment by said guest molecule.
According to one aspect, the hydrogel product is useful in a method of treating a patient suffering from a condition susceptible to treatment by a guest molecule, by administering to the patient a therapeutically effective amount of a hydrogel product according to the invention comprising said guest molecule.
According to another aspect, the hydrogel product is useful in a method of cosmetically treating skin, which comprises administering to the skin a hydrogel product according to the invention. Since the nature of the product obtainable by the processes according to the invention is complex, the product may also be defined as being the result of these processes.
The present invention furthermore provides an advantageous process of preparing a hydrogel product, comprising the steps of:
(a) providing (i) hyaluronic acid, (ii) dextran, and (iii) one or more cyclodextrin molecules;
(b) grafting the one or more cyclodextrin molecules onto the hyaluronic acid to form a cyclodextrin-grafted hyaluronic acid; and
(c) cross-linking the cyclodextrin-grafted hyaluronic acid to the dextran using a bi- or polyfunctional cross-linking agent.
In certain preferred embodiments, the cross-linking of step (c) provides ether bonds between the dextran and the cyclodextrin-grafted hyaluronic acid.
In some preferred embodiments, the grafting of step (b) provides amide bonds between the one or more cyclodextrin molecules and the hyaluronic acid.
Other preferred embodiments of steps (a) and (c) are evident from the description above relating to the resulting product. In particular, step (c) may further comprise size reduction of the cross-linked polymer mixture into particles, strings, discs, etc. In a preferred embodiment, the cross-linked polymer mixture is brought into the form of gel particles. The gel particles are obtained by reaction of dextran, cyclodextrin-grafted hyaluronic acid and a cross-linking reagent, e.g. BDDE under standard conditions. Particle size reduction of the resulting hydrogel followed by precipitation in ethanol induce the formation of such particles. The gel particles preferably have an average swelled size in the range of 0.01 -5 mm, preferably 0.1 -0.8 mm, such as 0.2- 0.5 mm or 0.5-0.8 mm.
It is preferred that the one or more cyclodextrin molecules of step (a) contain a linking group having an amino group, and wherein the linking group of the cyclodextrin molecule forms said amide bond with a carboxyl group of the hyaluronic acid. The linking group may contain a spacer, such as Ci-6 alkyl or Ci-4 alkyl. The linking group preferably is an amino group. Thus a preferred type of cyclodextrin molecules are aminocyclodextrin molecules as disclosed hereinabove.
In a preferred process, the grafting of step (b) involves:
(i) activating the carboxyl groups on the hyaluronic acid with a peptide coupling reagent to form an activated hyaluronic acid; and
(ii) coupling the linking group of the one or more cyclodextrin molecules to the carboxyl groups of the activated hyaluronic acid by amide bonds.
It has inventively been realized that the use of peptide coupling reagents on hyaluronic acid prior to the cross-linking step allows for an even distribution (grafting) of cyclodextrins in the final product via amide bonds to the cross-linked hyaluronic acid in the final product.
The one or more cyclodextrin molecules, such as aminocyclodextrin molecules, and the disaccharides of the cross-linked hyaluronic acid of the resulting hyaluronic acid product may have a molar ratio of 0.1 -50%, preferably 1 -20%, and more preferably 8-12%.
In the process, the activation of the hyaluronic acid and the coupling of the cyclodextrin molecule to the activated hyaluronic acid may occur simultaneously in step (b). Alternatively, the activation of the hyaluronic acid occurs prior to and separately from the coupling of the cyclodextrin molecule to the activated hyaluronic acid in step (b).
Preferred peptide coupling reagents are selected from the group consisting of triazine-based coupling reagents, carbodiimide coupling reagents, imidazolium-derived coupling reagents, Oxyma and COMU. Various other useful peptide coupling reagents are well known to the skilled person.
A particularly preferred group of peptide coupling reagent are triazine- based coupling reagents, such as 4-(4,6-dimethoxy-1 ,3,5-triazin-2-yl)-4- methylmorpholinium chloride (DMTMM) and 2-chloro-4,6-dimethoxy-1 ,3,5- triazine (CDMT). A particularly preferred triazine-based coupling reagent is DMTMM.
In a preferred embodiment, the amide bonds are formed between the amino group of amino-cyclodextrins having 6-8 glucopyranoside units and the carboxylic acid group of hyaluronic acid, followed by cross-linking with dextran and size reduction of the resulting gel to provide ether cross-linked dextran/hyaluronic acid gel particles with grafted cyclodextrins. This amide bond is realized by a peptide coupling agent, such as DMTMM.
The insights presented herein are also useful in a process of preparing a formulation of a guest molecule capable of forming a guest-host complex with a cyclodextrin host molecule, comprising the steps:
(a) providing (i) hyaluronic acid, (ii) dextran and (ii) one or more cyclodextrin host molecules capable of forming a guest-host complex with the guest molecule;
(b) grafting the one or more cyclodextrin host molecules onto the hyaluronic acid to form a cyclodextrin-grafted hyaluronic acid; and
c) cross-linking the cyclodextrin-grafted hyaluronic acid to the dextran using a bi- or polyfunctional cross-linking agent to form a cross-linked hydrogel. d) bringing a solution of the guest molecule into contact with the cyclodextrin host molecules grafted onto the hyaluronic acid under conditions allowing for the formation of a guest-host complex between the cyclodextrin host molecules and the guest molecule, and optionally
e) recovering the guest-host complex bound to the cross-linked hydrogel.
Non-limiting examples of pharmaceutical agents and cyclodextrins capable of forming guest-host complexes are provided in tables 1 -3.
Table 1 . Compiled from A. Maqnusdottir, M. Masson and T. Loftsson, J. Incl.
Phenom. Macrocvcl. Chem. 44, 213-218, 2002
Cyclodexthn type Drugs
a-Cyclodextrin Alprostadil (PGE1 )
Cefotiam hexetil HCI
β-Cyclodextrin Benexate HCI
Dexamethasone
Iodine
Nicotine
Nimesulide
Nitroglycerin
Omeprazol
PGE2
Piroxicam
Tiaprofenic acid
2-Hydroxypropyl- -cyclodextrin Cisapride
Hydrocortisone
Indomethacin
Itraconazole
Mitomycin I
Randomly methylated β-cyclodextrin 17 -Estradiol
Chloramphenicol
Sulfobutylether β-cyclodextrin Voriconazole
Ziprasidone maleate
2-Hydroxypropyl-y-cyclodextrin Diclofenac sodium
Figure imgf000021_0001
Figure imgf000022_0001
Table 3. Compiled from R. Arun et al. Sci Pharm. 2008; 76; 567-598.
Cyclodextrin type Drugs
β-CD Nimesulide, Sulfomethiazole,
Lorazepam, Ketoprofen,
Griseofulvin, Praziquantel,
Chlorthalidon, Exodolac,
Piroxicam, Itraconazole, Ibuprofen a-CD Praziquantel
Y-CD Praziquantel, Omeprazole, Digoxin
ΗΡ-β-CD Albendazole, DY-9760e, ETH-615,
Levemopamil HCI,
Sulfomethiazole, Ketoprofen, Griseofulvin, Itraconazole,
Carbamazepine Zolpidem,
Phenytoin, Rutin
ϋΜ-β-CD Naproxen, Camptothesin
SBE- -CD DY-9760e, Danazol, Fluasterone,
Spiranolactone
RM- -CD ETH-615, Tacrolimus
Randomly acetylated Naproxen
amorphous- -CD
ΗΡ-β-CD, ϋΜ-β-CD Promethazine
ΗΡ-β-CD 2-ethylhexyl p- (dimethylamino)benzoate β-CD Glibenclamide
β-CD Diclofenac sodium
β-CD, ΗΡ-β-CD Quinaril
ΗΡ-β-CD, HP-Y-CD Doxorubicin
ΗΡ-β-CD Acyl ester prodrugs of Ganciclovir
Y-CD Digoxin ΗΡ-β-CD Rutin
RDM- -CD Camptothesin
SBE- -CD, ΗΡ-β-CD Melphalan and Carmustine
Y-CD, HP-Y-CD, ΗΡ-β-CD Paclitaxel
SBE-a-CD, SBE- -CD, ΗΡ-β-CD, Spiranolactone
Y-CD, β-CD
β-CD Flutamide
β-CD Ketoprofen, Griseofulvin,
Terfenadine
ΗΡ-β-CD Albendazole, Ketoprofen,
Phenytoin, Gliclazide
SBE7^-CD Spiranolactone
ϋΜ-β-CD Tacrolimus
Μ-β-CD Albendazole
ΜΕ-β-CD Phenytoin
β-CD Terfanidine, Tolbutamide
ΗΡ-β-CD Tolbutamide,
Amylobarbitone
ΗΡ-β-CD Flutamide
Y-CD Digoxin
ΗΡ-β-CD Rutin
ΗΡ-β-CD Clomipramine,
Testosterone
SBE7^-CD, Danazole
ΗΡ-β-CD
β-CD Piroxicam
ϋΜ-β-CD Carbamazepine
Y-CD Digoxin
β-CD, SBE^-CD Glibenclamide
ΗΡ-β-CD Miconazole
Ε-β-CD, Glu^-CD, Phenytoin Mal- -CD, SBE- -CD, ΗΡ-β-CD
β-CD, y-CD, ϋΜ-β-CD, SBE- -CD, Spironolactone
ΗΡ-β-CD
β-CD, ΗΡ-β-CD Tolbutamide
ϋΜ-β-CD a-Tocopheryl; nicotinate
β-CD Acyclovir
ϋΜ-β-CD, ΗΡ-β-CD Diphenhydramine HCI
ϋΜ-β-CD Cyclosporin A
Explanation of abbreviations in Table 1-3:
β-CD, Beta cyclodextrin; ΗΡ-β-CD, Hydroxypropyl beta cyclodextrin; ϋΜ-β-CD, 2,6-di-O-methyl beta cyclodextrin; ΟΜ-β-CD, 6-O-maltosyl beta cyclodextrin; 2ΗΡ-β-ΰϋ, 2-hydroxypropyl beta cyclodextrin; HP-a-CD, Hydroxypropyl alpha cyclodextrin; a-CD, Alpha cyclodextrin; γ-CD, Gamma cyclodextrin; Μ-β-CD, Methyl-β-cyclodextrin; SB^-CD, Sulfobutyl beta cyclodextrin; Y-CDC6, Gamma cyclodextrin C6 or amphiphilic 2,3-di-O- hexanoyl gamma cyclodextrin; β-CDMCT, Monochlorotriazinyl beta cyclodextrin; Heptakis^-CD, Heptakis (2-x-amino-O-oligo (ethylene oxide)-6- hexylthio) beta cyclodextrin; bis-CDs, Ethylenediamino or diethylenetriamino bridged bis(beta cyclodextrin)s; RIV^-CD, randomly methylated beta cyclodextrin; (SBE)7m^-CD, Sulfobutyl ether^-cyclodextrin; MCT^-CD, Monochlorotriaziny beta cyclodextrin; Μβ-β-CD, Methyl beta cyclodextrin; SBE^-CD, Sulfobutylether-β-cyclodextrin; TPPS, Anionic 5,10,15,20- tetrakis(4- sulfonatophenyl)-21 H,23H-porphyrin; Ε-β-CD, β-Cyclodextrin epichlorohydrin polymer; Glu^-CD, Glucosyl-β-cyclodextrin; Mal^-CD, Maltosyl^-cyclodextrin. Without desiring to be limited thereto, the present invention will in the following be illustrated by way of examples. Examples
Example 1 - Grafting of 6-amino-gamma-CD to HA, followed by cross-linking to d extra n
DMTMM (0.3 g) and 6-amino-gamma-CD (0.8 g) are dissolved in phosphate-buffered saline (PBS) (25 ml_), and the pH of the solution is adjusted to approx. 6.5 (1 .2 M HCI). This solution is added to dry HA powder (0.3 g) and then stirred gently. The reaction is heated to 45°C for 24 h and then allowed to cool down to room temperature. The product is washed twice with PBS (15 mL/g gel) and filtrated. The product is then washed three times with ethanol 70 % (15 mL/g gel) and the solution is discarded.
Dextran powder (0.1 g) is dissolved in PBS (25 ml), and the pH of the solution is adjusted to approx. 9.0 using NaOH. This solution is added to the cyclodextrin-grafted HA and then stirred gently. Cross-linking reagent BDDE is added and allowed to react with the the polymer mixture in solution, forming a gel. The gel is washed twice with PBS (15 mL/g gel) and filtrated. The gel is then washed three times with ethanol 70 % (15 mL/g gel) and the solution is discarded. Finally, pure ethanol is added to the gel and filtrated and dried under vacuum to yield the final material.
Example 2- Characterization of HA-cyclodextrin-dextran product
The HA-cyclodextrin-dextran gel obtained in Example 1 is characterized by the swelling, i.e. the ability to absorb water, and the viscoelastic properties. Swelling is expressed as the amount of water in gram that one gram dry cross-linked HA-dextran polymer can absorb. The viscoelastic properties are measured by rheometry, and are expressed as the storage modulus (G') and the loss modulus (G").
The chemical composition of the HA-cyclodextrin-dextran is obtained by proton NMR spectroscopy after degradation of the HA polysaccharide strands by hylauronidase or equivalent to obtain sharp lines in the spectrum enabling proper quantification. The chemical linking between HA, dextran and cyclodext n is characterized by size exclusion chromatography coupled to mass spectrometry after degradation by both hylauronidase and dextranase or equivalent. Example 3 - Grafting of 3-amino-gamma-CD to HA, followed by cross-linking to dextran
Step 1 : Grafting of cyclodexthn to hyaluronan
The 3-amino-y-cyclodextrin was dissolved together with the activation agent DMTMM in 1 mM PBS buffer. 1 MDa Hyaluronan (HA) was dissolved in the same solution. The reaction mixture was stirred and allowed to react. The reaction was stopped by the addition of ethanol under vigorous stirring. The precipitate was isolated by decantation, washed with 70% ethanol (w/w) then with pure ethanol and dried in a vacuum oven at 23 °C over night.
The cyclodexthn conjugated hyaluronan was analysed by 1H-NMR after enzymatic degradation of the polymer with chondroitinase ABC. A modification degree (cyclodextrin per hyaluronan disaccharide, (MOD CDx/HAdi)) of 8 to 12 % was obtained. Step 2 formation of a hydrogel by cross-linking a mixture of modified hyaluronan and dextran.
Cyclodextrin-conjugated HA having a modification degree (MOD
CDx/HAdi) of 12 % was placed together with Dextran 250 kDa in a flask and mixed with a solution of BDDE dissolved in 1 % (w/w) NaOH. The solution was stirred until a gel was obtained, and the resulting gel was passed through a grid for particle size reduction. The resulting particles were allowed to swell in a 10 mM PBS solution.
Results
1H-NMR after enzymatic degradation of the gel showed that the cyclodextrin content remained constant. Signals from cyclodextrin and dextran overlap in the 1H-NMR spectrum.
Figure imgf000028_0001
e ex ran sacc ar e s re a e o e ya uronan sacc ar e.
Itemized listing of preferred embodiments
1 . New hydrogel comprising hyaluronic acid (HA) grafted with amino- cydodextrins.
2. Hydrogel according to emodiment 1 characterized that it is linked to dextran. 3. Process to obtain hydrogel according to embodiment 1 comprising the following steps :
a) Grafting between HA and amino-cyclodextrin bearing a spacer or not is made by using peptidic coupling. 4. Process to obtain hydrogel according to embodiment 2 comprising the following steps :
a) Grafting between HA and amino-cyclodextrin is made by using peptidic coupling
b) The functionalized polysaccharide obtained at step a) is linked to dextran by the use of a diepoxide linker like butanediol diglycidyl ether
(BDDE).
5. Hydrogel according to embodiment 1 or 2 wherein the amino-cyclodextrins is Alpha-CD, beta-CD or gamma-CD.
6. Hydrogel according to embodiment 1 or 2 wherein the amino cydodextrins are functionalized in position 6. 7. Hydrogel according to embodiment 1 or 2 wherein the hyaluronic acid derivatized with amino-cyclodextrins have a degree of modification comprised between 0.1 and 50%, more preferably between 1 and 20%.
8. Use of the hydrogel according to embodiment 1 or 2 for the preparation of pharmaceutical forms or medical devices involving the transport or the controlled release of drugs and/or biologically active substances. 9. Use of hydrogel according to embodiment 8 wherein the active substances are anti-infective agents, antimicrobials, anti-inflammatory agents, cytostatic, cytotoxic, antiviral, anesthetic, hemostatic, vasoconstrictor agents or growth factors. 10. Use of hydrogel according to embodiment 8 or 9 wherein the active substance is retinol.
1 1 . Use of hydrogel according to any of embodiment 1 to 10 in the treatment of disorders in the field of dermatology, aesthetics, ophthalmology, gynecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology.

Claims

1 . A hydrogel product comprising (a) one or more cyclodextrin molecules grafted to hyaluronic acid and (b) dextran, wherein the cyclodextrin-grafted hyaluronic acid is cross-linked to the dextran.
2. A hydrogel product according to claim 1 , wherein the cyclodextrin-grafted hyaluronic acid is cross-linked to the dextran by ether bonds.
3. A hydrogel product according to any one of claims 1 -2, wherein the one or more cyclodextrin molecules are grafted onto the hyaluronic acid by amide bonds.
4. A hydrogel product according to any one of claims 1 -3, which is in the form of particles having an average size in the range of 0.01 -5 mm, preferably 0.1 -
0.8 mm.
5. A hydrogel product according to any one of claims 1 -4, wherein the cyclodextrin-grafted hyaluronic acid has a molar ratio of 0.1 -50%, preferably 1 -20%, and more preferably 8-12%, between the one or more cyclodextrin molecules and the disaccharides of the hyaluronic acid.
6. A hydrogel product according to any one of claims 1 -5, wherein the dextran and the hyaluronic acid chains are cross-linked to each other via a linking group which is derived from a bi- or polyfunctional cross-linking agent.
7. A hydrogel product according to claim 6, wherein said bi- or polyfunctional cross-linking agent is a bis- or polyepoxide.
8. A hydrogel product according to claim 7, wherein said bi- or polyfunctional cross-linking agent is a diglycidyl ether.
9. A hydrogel product according to claim 8, wherein said bi- or polyfunctional cross-linking agent is selected from the group consisting of 1 ,4-butanediol diglycidyl ether (BDDE), 1 ,2-bis(2,3-epoxypropoxy)ethylene (EGDGE) and ethylene glycol diglycidyl ether (EGDE), 1 ,2-ethanediol diglycidyl ether (EDDE) and diepoxyoctane.
10. A hydrogel product according to claim 9, wherein said bi- or polyfunctional cross-linking agent is 1 ,4-butanediol diglycidyl ether (BDDE).
1 1 . A hydrogel product according to any one of claims 1 -10, wherein the cyclodextrin molecule contains a linking group having an amino group, and wherein the linking group of the cyclodextrin molecule forms said amide bond with a carboxyl group of the hyaluronic acid.
12. A hydrogel product according to claim 1 1 , wherein the linking group contains a Ci-6 alkyl.
13. A hydrogel product according to claim 12, wherein the linking group contains a Ci-4 alkyl.
14. A hydrogel product according to claim 1 1 , wherein the cyclodextrin molecule is an aminocyclodextrin molecule, and wherein an amino group of the aminocyclodextrin molecules forms said amide bond with a carboxyl group of the hyaluronic acid.
15. A hydrogel product according to any one of claims 1 -14, wherein the cyclodextrin molecule is constituted by 5-32 glucopyranoside units.
16. A hydrogel product according to claim 15, wherein the cyclodextrin molecule is constituted by 6-8 glucopyranoside units.
17. A hydrogel product according to claim 16, wherein the cyclodextrin molecule is constituted by 6 glucopyranoside units (a-cyclodextrin).
18. A hydrogel product according to claim 16, wherein the cyclodextrin molecule is constituted by 7 glucopyranoside units (β-cyclodextrin).
19. A hydrogel product according to claim 16, wherein the cyclodextrin molecule is constituted by 8 glucopyranoside units (γ-cyclodextrin).
20. A hydrogel product according to any one of claims 16-19, wherein the cyclodextrin molecule is selected from the group consisting of
2-aminocyclodextrin, 3-aminocyclodextrin and 6-aminocyclodextrin.
21 . A hydrogel product according to claim 20, wherein the cyclodextrin molecule is selected from the group consisting of 3-aminocyclodextrin and 6-aminocyclodextrin.
22. A hydrogel product according to claim 21 , wherein the cyclodextrin molecule is 6-aminocyclodextrin.
23. A hydrogel product according to any one of claims 1 -22, further comprising a guest molecule capable of forming a guest-host complex with the cyclodextrin molecule acting as a host.
24. A hydrogel product according to claim 23, wherein the guest molecule is selected from drugs and/or biologically active substances used in the treatment of disorders in the field of dermatology, aesthetics, ophthalmology, gynaecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology, such as anti-infective agents, antimicrobials, antiinflammatory agents, cytostatic, cytotoxic, antiviral, anaesthetic, hemostatic, vasoconstrictor agents or growth factors.
25. A hydrogel product according to claim 23, wherein the guest molecule is a vitamin A molecule.
26. A hydrogel product according to claim 25, wherein the guest molecule is retinol or retinoic acid, or an ester or an ether thereof.
27. A hydrogel product according to any one claims 23-26 for use as a medicament.
28. A hydrogel product according to claim 27 for use in the treatment of a condition susceptible to treatment by said guest molecule.
29. Use of a hydrogel product according to any one of claims 23-26, for the manufacture of a medicament for treatment of a condition susceptible to treatment by said guest molecule.
30. Use of the hydrogel product according to any one of claims 23-26 for the preparation of pharmaceutical forms or medical devices involving the transport or the controlled release of said guest molecule.
31 . A method of treating a patient suffering from a condition susceptible to treatment by a guest molecule by administering to the patient a
therapeutically effective amount of a hydrogel product according to any one of claims 23-26 comprising said guest molecule.
32. A method of cosmetically treating skin, which comprises administering to the skin a hydrogel product according to any one of claims 23-26.
33. A process of preparing a hydrogel product, comprising the steps of:
(a) providing (i) hyaluronic acid, (ii) dextran, and (iii) one or more cyclodextnn molecules;
(b) grafting the one or more cyclodextrin molecules onto the hyaluronic acid to form a cyclodextrin-grafted hyaluronic acid; and
(c) cross-linking the cyclodextrin-grafted hyaluronic acid to the dextran using a bi- or polyfunctional cross-linking agent.
34. A process according to claim 33, wherein the cross-linking of step (c) provides ether bonds between the dextran and the cyclodextrin-grafted hyaluronic acid.
35. A process according to any one of claims 33-34, wherein the grafting of step (b) provides amide bonds between the one or more cyclodextrin molecules and the hyaluronic acid.
36. A process according to any one of claims 33-35, wherein step (c) further comprises providing particles of the cross-linked hydrogel product, having an average size in the range of 0.01 -5 mm, preferably 0.1-0.8 mm.
37. A process according to any one of claims 33-36, wherein the one or more cyclodextrin molecules and the disaccharides of the cross-linked hyaluronic acid of the resulting hydrogel product have a molar ratio of 0.1 -50%, preferably 1 -20%, and more preferably 8-12%.
38. A process according to any one of claims 33-37, wherein the one or more cyclodextrin molecules of step (a) contain a linking group having an amino group, and wherein the linking group of the cyclodextrin molecule forms said amide bond with a carboxyl group of the hyaluronic acid.
39. A process according to claim 38, wherein the linking group contains a Ci-6 alkyl.
40. A process according to claim 39, wherein the linking group contains a Ci-4 alkyl.
41. A process according to claim 38, wherein the one or more cyclodextrin molecules of step (a) are aminocyclodextrin molecules.
42. A process according to any one of claims 38-41 , wherein the grafting of step (b) involves: (i) activating the carboxyl groups on the hyaluronic acid with a peptide coupling reagent to form an activated hyaluronic acid; and
(ii) coupling the linking group of the one or more cyclodextrin molecules to the carboxyl groups of the activated hyaluronic acid by amide bonds.
43. A process according to claim 42, wherein the activation of the hyaluronic acid and the coupling of the cyclodextrin molecule to the activated hyaluronic acid occur simultaneously in step (b).
44. A process according to claim 42, wherein the activation of the hyaluronic acid occur prior to and separately from the coupling of the cyclodextrin molecule to the activated hyaluronic acid in step (b).
45. A process according to any one of claims 42-44, wherein the peptide coupling reagent is selected from the group consisting of triazine-based coupling reagents, carbodiimide coupling reagents, imidazolium-derived coupling reagents, Oxyma and COMU.
46. A process according to claim 45, wherein the peptide coupling reagent is a triazine-based coupling reagent.
47. A process according to claim 46, wherein the triazine-based coupling reagent is selected from the group consisting of 4-(4,6-dimethoxy-1 ,3,5- triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) and 2-chloro-4,6- dimethoxy-1 ,3,5-triazine (CDMT).
48. A process according to claim 47, wherein the triazine-based coupling reagent is DMTMM.
49. A process according to any one of claims 33-48, wherein the bi- or polyfunctional crosslinking agent of step (c) is a bis- or polyepoxide.
50. A process according to claim 49, wherein said bi- or polyfunctional cross- linking agent is a diglycidyl ether.
51 . A process according to claim 50, wherein said bi- or polyfunctional cross- linking agent is selected from the group consisting of 1 ,4-butanediol diglycidyl ether (BDDE), 1 ,2-bis(2,3-epoxypropoxy)ethylene (EGDGE) and ethylene glycol diglycidyl ether (EGDE), 1 ,2-ethanediol diglycidyl ether (EDDE) and diepoxyoctane.
52. A process according to claim 51 , wherein said bi- or polyfunctional cross- linking agent is 1 ,4-butanediol diglycidyl ether (BDDE).
53. A process according to any one of claims 33-52, wherein the cyclodextrin molecule is constituted by 5-32 glucopyranoside units.
54. A process according to claim 53, wherein the cyclodextrin molecule is constituted by 6-8 glucopyranoside units.
55. A process according to claim 54, wherein the cyclodextrin molecule is constituted by 6 glucopyranoside units (a-cyclodextrin).
56. A process according to claim 54, wherein the cyclodextrin molecule is constituted by 7 glucopyranoside units (β-cyclodextrin).
57. A process according to claim 54, wherein the cyclodextrin molecule is constituted by 8 glucopyranoside units (γ-cyclodextrin).
58. A process according to any one of claims 54-57, wherein the cyclodextrin molecule is selected from the group consisting of 2-aminocyclodextrin, 3- aminocyclodextrin and 6-aminocyclodextrin.
59. A process according to claim 58, wherein the cyclodextrin molecule is selected from the group consisting of 3-aminocyclodextrin and
6-aminocyclodextrin.
60. A process according to claim 59, wherein the cyclodextrin molecule is 6-aminocyclodextrin.
61 . A process of preparing a formulation of a guest molecule capable of forming a guest-host complex with a cyclodextrin host molecule, comprising the steps:
(a) providing (i) hyaluronic acid, (ii) dextran and (ii) one or more cyclodextrin host molecules capable of forming a guest-host complex with the guest molecule;
(b) grafting the one or more cyclodextrin host molecules onto the hyaluronic acid to form a cyclodextrin-grafted hyaluronic acid; and
c) cross-linking the cyclodextrin-grafted hyaluronic acid to the dextran using a bi- or polyfunctional cross-linking agent to form a cross-linked hydrogel. d) bringing a solution of the guest molecule into contact with the cyclodextrin host molecules grafted onto the hyaluronic acid under conditions allowing for the formation of a guest-host complex between the cyclodextrin host molecules and the guest molecule, and optionally
e) recovering the guest-host complex bound to the cross-linked hydrogel.
62. A process according to claim 61 , wherein the cross-linking of step (c) provides ether bonds between the dextran and the cyclodextrin-grafted hyaluronic acid.
63. A process according to any one of claims 61 -62, wherein the grafting of step (b) provides amide bonds between the one or more cyclodextrin molecules and the hyaluronic acid.
64. A process according to any one of claims 61 -63, wherein the guest molecule is selected from drugs and/or biologically active substances used in the treatment of disorders in the field of dermatology, aesthetics,
ophthalmology, gynaecology, oncology, angiology, neurology, orthopaedics, rheumatology or aesthetic dermatology, such as anti-infective agents, antimicrobials, anti-inflammatory agents, cytostatic, cytotoxic, antiviral, anaesthetic, hemostatic, vasoconstrictor agents or growth factors.
65. A process according to any one of claims 61 -64, wherein the guest molecule is a cosmetic agent.
66. A process according to any one of claims 61 -65, wherein the guest molecule is a vitamin A molecule.
67. A process according to claim 66, wherein the guest molecule is retinol or retinoic acid, or an ester or an ether thereof.
68. Product obtainable by the process according to any one of claims 61 -67.
PCT/EP2015/061999 2014-05-29 2015-05-29 Cyclodextrin-grafted hyaluronic acid crosslinked with dextran and uses thereof WO2015181365A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP15726137.1A EP3148600B1 (en) 2014-05-29 2015-05-29 Cyclodextrin-grafted hyaluronic acid crosslinked with dextran and uses thereof
US15/314,823 US20170196991A1 (en) 2014-05-29 2015-05-29 Cyclodextrin-grafted hyaluronic acid crosslinked with dextran and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462004293P 2014-05-29 2014-05-29
US62/004,293 2014-05-29
EP14198951 2014-12-18
EP14198951.7 2014-12-18

Publications (1)

Publication Number Publication Date
WO2015181365A1 true WO2015181365A1 (en) 2015-12-03

Family

ID=52272868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/061999 WO2015181365A1 (en) 2014-05-29 2015-05-29 Cyclodextrin-grafted hyaluronic acid crosslinked with dextran and uses thereof

Country Status (3)

Country Link
US (1) US20170196991A1 (en)
EP (1) EP3148600B1 (en)
WO (1) WO2015181365A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097211A1 (en) * 2014-12-18 2016-06-23 Galderma S.A. Grafting of cyclodextrin by amide bonds to an ether cross-linked hyaluronic acid and uses thereof
WO2016192760A1 (en) * 2015-05-29 2016-12-08 Galderma S.A. Mixed hydrogels of hyaluronic acid and dextran
WO2017114865A1 (en) * 2015-12-29 2017-07-06 Galderma S.A. Hydrolysis of ester bonds in amide crosslinked glycosaminoglycans
EP3252081A1 (en) * 2016-05-31 2017-12-06 Galderma S.A. Hydrolysis of ester bonds in amide crosslinked glycosaminoglycans
WO2017220622A1 (en) 2016-06-23 2017-12-28 Galderma S.A. Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
US10058502B2 (en) 2015-12-31 2018-08-28 L'oreal Nail polish compositions
IT201800007683A1 (en) * 2018-07-31 2020-01-31 Altergon Sa Synergistic cooperative compositions useful for soft tissue augmentation, drug release and related fields
US10954316B2 (en) 2016-05-31 2021-03-23 Galderma Holding SA Method for cleaving amide bonds
CN113350575A (en) * 2021-06-23 2021-09-07 安徽医科大学第一附属医院 Organic-inorganic composite hydrogel for regulating local bone metabolism, preparation method and application thereof
US11730691B2 (en) 2019-12-02 2023-08-22 Galderma Holding SA High molecular weight esthetic compositions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494648B (en) * 2020-05-14 2021-10-22 清华大学 Lubrication medicine-carrying nanosphere, medicine and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046252A1 (en) * 1999-02-05 2000-08-10 Vitrolife Uk Limited Process for cross-linking hyaluronic acid to polymers
US20020192182A1 (en) * 2001-03-12 2002-12-19 Stephen Massia Polysaccharide-based polymerizable hydrogels
US20130231474A1 (en) * 2010-11-18 2013-09-05 Universite Joseph Fourier - Grenoble 1 Polysaccharide derivatives including an alkene unit and thiol-click chemical coupling reaction
US20140094433A1 (en) * 2012-10-02 2014-04-03 Allergan, Inc. Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046252A1 (en) * 1999-02-05 2000-08-10 Vitrolife Uk Limited Process for cross-linking hyaluronic acid to polymers
US20020192182A1 (en) * 2001-03-12 2002-12-19 Stephen Massia Polysaccharide-based polymerizable hydrogels
US20130231474A1 (en) * 2010-11-18 2013-09-05 Universite Joseph Fourier - Grenoble 1 Polysaccharide derivatives including an alkene unit and thiol-click chemical coupling reaction
US20140094433A1 (en) * 2012-10-02 2014-04-03 Allergan, Inc. Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHARLOT A ET AL: "Controlled synthesis and inclusion ability of a hyaluronic acid derivative bearing beta-cyclodextrin molecules", BIOMACROMOLECULES, AMERICAN CHEMICAL SOCIETY, US, vol. 7, no. 3, 1 March 2006 (2006-03-01), pages 907 - 913, XP002728110, ISSN: 1525-7797, [retrieved on 20060210], DOI: 10.1021/BM0507094 *
JIN R ET AL: "Enzymatically-crosslinked injectable hydrogels based on biomimetic dextran@?hyaluronic acid conjugates for cartilage tissue engineering", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 31, no. 11, 1 April 2010 (2010-04-01), pages 3103 - 3113, XP026933236, ISSN: 0142-9612, [retrieved on 20100208], DOI: 10.1016/J.BIOMATERIALS.2010.01.013 *
LAURA PESCOSOLIDO ET AL: "Hyaluronic Acid and Dextran-Based Semi-IPN Hydrogels as Biomaterials for Bioprinting", BIOMACROMOLECULES, vol. 12, no. 5, 9 May 2011 (2011-05-09), pages 1831 - 1838, XP055207927, ISSN: 1525-7797, DOI: 10.1021/bm200178w *
SOLTES L ET AL: "Cyclodextrin derivative of hyaluronan", CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 39, no. 1, 1 May 1999 (1999-05-01), pages 17 - 24, XP004160582, ISSN: 0144-8617, DOI: 10.1016/S0144-8617(98)00135-0 *
ZAWKO S A ET AL: "Drug-binding hydrogels of hyaluronic acid functionalized with beta-cyclodextrin", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART A, JOHN WILEY & SONS, INC, US, vol. 87, no. 4, 15 December 2008 (2008-12-15), pages 1044 - 1052, XP002728107, ISSN: 1552-4965, [retrieved on 20080206], DOI: 10.1002/JBM.A.31845 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097211A1 (en) * 2014-12-18 2016-06-23 Galderma S.A. Grafting of cyclodextrin by amide bonds to an ether cross-linked hyaluronic acid and uses thereof
US10533061B2 (en) 2014-12-18 2020-01-14 Galderma S.A. Grafting of cyclodextrin by amide bonds to an ether cross-linked hyaluronic acid and uses thereof
WO2016192760A1 (en) * 2015-05-29 2016-12-08 Galderma S.A. Mixed hydrogels of hyaluronic acid and dextran
US11939433B2 (en) 2015-12-29 2024-03-26 Galderma Holding S.A. Method for preparing acylated crosslinked glycosaminoglycans
US11780970B2 (en) 2015-12-29 2023-10-10 Galderma Holding S.A. Carbohydrate crosslinker
US11066526B2 (en) 2015-12-29 2021-07-20 Galderma Holding SA Method for cleaving amide bonds
WO2017114865A1 (en) * 2015-12-29 2017-07-06 Galderma S.A. Hydrolysis of ester bonds in amide crosslinked glycosaminoglycans
US11708461B2 (en) 2015-12-29 2023-07-25 Galderma Holding SA Method for preparing acylated crosslinked glycosaminoglycans
US11643509B2 (en) 2015-12-29 2023-05-09 Galderma Holding SA Carbohydrate crosslinker
US10899894B2 (en) 2015-12-29 2021-01-26 Galderma S.A Method for preparing acylated crosslinked glycosaminoglycans
US11530301B2 (en) 2015-12-29 2022-12-20 Galderma Holding SA Carbohydrate crosslinker
US11254792B2 (en) 2015-12-29 2022-02-22 Galderma Holding SA Method for deacetylation of biopolymers
US11198765B2 (en) 2015-12-29 2021-12-14 Galderma Holding SA Hydrolysis of ester bonds in amide crosslinked glycosaminoglycans
US10058502B2 (en) 2015-12-31 2018-08-28 L'oreal Nail polish compositions
US10954316B2 (en) 2016-05-31 2021-03-23 Galderma Holding SA Method for cleaving amide bonds
EP3252081A1 (en) * 2016-05-31 2017-12-06 Galderma S.A. Hydrolysis of ester bonds in amide crosslinked glycosaminoglycans
US10988600B2 (en) 2016-06-23 2021-04-27 Galderma Holding SA Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
WO2017220622A1 (en) 2016-06-23 2017-12-28 Galderma S.A. Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
CN112584868A (en) * 2018-07-31 2021-03-30 阿尔特贡股份公司 Synergistic cooperative compositions, drug delivery and related fields to aid soft tissue augmentation/enhancement
WO2020025415A1 (en) * 2018-07-31 2020-02-06 Altergon S.A. Synergistically cooperative compositions useful for soft tissue augmentation, drug delivery and related fields
IT201800007683A1 (en) * 2018-07-31 2020-01-31 Altergon Sa Synergistic cooperative compositions useful for soft tissue augmentation, drug release and related fields
US11730691B2 (en) 2019-12-02 2023-08-22 Galderma Holding SA High molecular weight esthetic compositions
CN113350575A (en) * 2021-06-23 2021-09-07 安徽医科大学第一附属医院 Organic-inorganic composite hydrogel for regulating local bone metabolism, preparation method and application thereof

Also Published As

Publication number Publication date
EP3148600B1 (en) 2019-08-07
US20170196991A1 (en) 2017-07-13
EP3148600A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
US10533061B2 (en) Grafting of cyclodextrin by amide bonds to an ether cross-linked hyaluronic acid and uses thereof
EP3148600B1 (en) Cyclodextrin-grafted hyaluronic acid crosslinked with dextran and uses thereof
Li et al. Bioactive polysaccharides from natural resources including Chinese medicinal herbs on tissue repair
WO2014198683A2 (en) Ha with cyclodextrins
WO2015181366A1 (en) Cross-linked polymer mixture of hyaluronic acid and dextran grafted with cyclodextrins and uses thereof
Rinaudo Main properties and current applications of some polysaccharides as biomaterials
Van De Manakker et al. Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications
EP1873167A2 (en) Method of obtaining hydrogels of cyclodextrins with glycidyl ethers, compositions thus obtained and applications thereof
Auzely-Velty Self-assembling polysaccharide systems based on cyclodextrin complexation: Synthesis, properties and potential applications in the biomaterials field
EP1272530A1 (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
Tonegawa et al. Emerging nanoassembly of polyrotaxanes comprising acetylated α-cyclodextrins and high-molecular-weight axle polymer
EP4038105B1 (en) A hyperbranched polyglycerol polyglycidyl ether and its use as crosslinker for polysaccharides
Thomas et al. Chemical modification of chitosan and its biomedical application
Kim et al. Recent studies on modulating hyaluronic acid-based hydrogels for controlled drug delivery
WO2019002369A1 (en) Glycosaminoglycan hydrogel with grafted dextran or cyclodextrin
Kumar et al. Polysaccharide nanoconjugates for drug solubilization and targeted delivery
Luzardo-Alvarez et al. Cyclodextrin-based polysaccharidic polymers: an approach for the drug delivery
Kłodzińska et al. Hyaluronic acid-based nanosystems for drug delivery applications
EP3475312B1 (en) Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
Vandera et al. Formation of Supramolecular Gels from Host–Guest Interactions between PEGylated Chitosan and α‐Cyclodextrin
Ansari et al. Polysaccharide nanoconjugates in drug delivery
Cordaro Engineered Biomaterials based on Hyaluronic Acid and Cyclodextrin Supramolecular Assemblies for Therapy and Diagnosis
Kumar et al. ⁎ Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET), Meerut, India,† Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard (Hamdard University), New Delhi, India
Rodrigues Production of Nanoparticles by Polyelectrolyte Complexation from Novel Locust Bean Gum Cationic Derivatives
CZ2007606A3 (en) Preparation process of cyclodextrin-modified hyaluronate and application thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15726137

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015726137

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15314823

Country of ref document: US

Ref document number: 2015726137

Country of ref document: EP